Bristol Myers Squibb Receives FDA Priority Review for Camzyos in Hypertrophic Cardiomyopathy
The U.S. Food and Drug Administration (FDA) has accepted Bristol Myers Squibb's supplemental New Drug Application (sNDA) for Camzyos, granting it a Priority Review designation for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adolescents.
Tickers: $BMY
Topics: cardiology pharmaceuticals